Morepen Labs 41st AGM: Key Resolutions Passed Including Dividend and Management Re-appointments
Morepen Laboratories Limited's 41st AGM on September 26, 2026, saw the passing of resolutions for annual accounts adoption and a ₹0.20 dividend. Key management changes included Mr. Sanjay Suri's appointment as MD and Mr. Sushil Suri's re-appointment as CMD. The medical devices business hive-off timeline was also extended.
The passing of resolutions related to dividend, management appointments, and business restructuring has a moderate impact on the company's governance and strategic direction.
The announcement details the successful conclusion of the AGM with all resolutions passed, including dividend declaration and key management appointments, indicating smooth corporate governance.
Morepen Laboratories Limited held its 41st Annual General Meeting (AGM) on Saturday, September 26, 2026, through video conferencing. The meeting, which commenced at 1:00 PM, concluded by 2:15 PM. Shareholders had the opportunity to vote on seven resolutions, including the adoption of annual accounts for the financial year ended March 31, 2026, and the declaration of a final dividend of ₹0.20 per equity share.
Key decisions made during the AGM include the appointment of Mr. Sanjay Suri as a director and his subsequent elevation from Whole-Time Director to Managing Director. Furthermore, Mr. Sushil Suri was re-appointed as the Chairman & Managing Director. The shareholders also ratified the remuneration of M/s. Vijender Sharma & Co. as Cost Auditors for the financial year 2026-27.
Additionally, a special resolution was passed to extend the approved timeline for hiving off the company's Medical Devices Business into its subsidiary, Morepen Medipath Limited, on a slump sale basis. The e-voting facility was provided from September 23, 2026, to September 25, 2026, with an additional window during the AGM. The consolidated Scrutinizer’s Report, dated September 26, 2026, confirmed the passing of all resolutions.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.